Please assess the completion status of the following clinical trial:

Trial Title: Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants with congenital CMV infection and hearing loss (≥ 20 dB, in one or both ears).~* Age at time of inclusion is \< 13 weeks after birth.~* ≥ 37 weeks gestational age.~* Birth weight ≥ 2500 gram.~* Parental signed informed consent.~Exclusion Criteria:~* Indications for symptomatic congenital CMV infection based on diagnostics carried out prior to the inclusion of the child in the trial.~* In case during the house visit the presence of a symptomatic CMV infection is doubted, inclusion will be discussed. Depending on the medical history taking, physical examination and laboratory tests inclusion will be decided upon.~* Treatment with other antiviral agents or immunoglobulins.~* Leucopenia \< 0,5 x 10\*9/L (blood sample tested at t=0).

- Gender: ALL
- Minimum Age: 3 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: f

Study Arms:
- Valganciclovir (Type: EXPERIMENTAL): Valganciclovir 32 mg/kg per day in two doses (16 mg/kg per dose) during 6 weeks in an oral solution.
- Control (Type: NO_INTERVENTION): Infants in the control group receive no antiviral therapy. Counseling and treatment assigned by an audiological center remains unchanged.

Based on this trial design, predict the completion outcome and termination type (if applicable).